199 related articles for article (PubMed ID: 12751635)
21. Optimisation of culture conditions to develop an in vitro pulmonary permeability model.
Geys J; Nemery B; Hoet PH
Toxicol In Vitro; 2007 Oct; 21(7):1215-9. PubMed ID: 17629671
[TBL] [Abstract][Full Text] [Related]
22. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
Kolanjiyil AV; Kleinstreuer C; Sadikot RT
Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
[TBL] [Abstract][Full Text] [Related]
23. In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models.
Acosta MF; Muralidharan P; Meenach SA; Hayes D; M-Black S; Mansour HM
Curr Pharm Des; 2016; 22(17):2522-31. PubMed ID: 26831643
[TBL] [Abstract][Full Text] [Related]
24. Drug absorption by the respiratory mucosa: cell culture models and particulate drug carriers.
Ehrhardt C; Fiegel J; Fuchs S; Abu-Dahab R; Schaefer UF; Hanes J; Lehr CM
J Aerosol Med; 2002; 15(2):131-9. PubMed ID: 12184863
[TBL] [Abstract][Full Text] [Related]
25. Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs.
Mamlouk M; Young PM; Bebawy M; Haghi M; Mamlouk S; Mulay V; Traini D
J Asthma; 2013 May; 50(4):334-41. PubMed ID: 23406450
[TBL] [Abstract][Full Text] [Related]
26. Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines.
Rigo LA; Carvalho-Wodarz CS; Pohlmann AR; Guterres SS; Schneider-Daum N; Lehr CM; Beck RCR
Eur J Pharm Biopharm; 2017 Oct; 119():1-10. PubMed ID: 28512018
[TBL] [Abstract][Full Text] [Related]
27. Targeted drug aerosol deposition analysis for a four-generation lung airway model with hemispherical tumors.
Kleinstreuer C; Zhang Z
J Biomech Eng; 2003 Apr; 125(2):197-206. PubMed ID: 12751281
[TBL] [Abstract][Full Text] [Related]
28. Development of an in vitro model of human bronchial epithelial barrier to study nanoparticle translocation.
George I; Vranic S; Boland S; Courtois A; Baeza-Squiban A
Toxicol In Vitro; 2015 Feb; 29(1):51-8. PubMed ID: 25197033
[TBL] [Abstract][Full Text] [Related]
29. Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies.
Marin L; Traini D; Bebawy M; Colombo P; Buttini F; Haghi M; Ong HX; Young P
Eur J Pharm Biopharm; 2013 Aug; 84(3):566-72. PubMed ID: 23474382
[TBL] [Abstract][Full Text] [Related]
30. The formulation of a pressurized metered dose inhaler containing theophylline for inhalation.
Zhu B; Haghi M; Goud M; Young PM; Traini D
Eur J Pharm Sci; 2015 Aug; 76():68-72. PubMed ID: 25956075
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-β
Togami K; Yamaguchi K; Chono S; Tada H
J Pharmacol Toxicol Methods; 2017 Jul; 86():19-27. PubMed ID: 28259823
[TBL] [Abstract][Full Text] [Related]
32. Bioengineering of therapeutic aerosols.
Edwards DA; Dunbar C
Annu Rev Biomed Eng; 2002; 4():93-107. PubMed ID: 12117752
[TBL] [Abstract][Full Text] [Related]
33. Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers.
Foraker AB; Walczak RJ; Cohen MH; Boiarski TA; Grove CF; Swaan PW
Pharm Res; 2003 Jan; 20(1):110-6. PubMed ID: 12608544
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery.
Foster KA; Avery ML; Yazdanian M; Audus KL
Int J Pharm; 2000 Nov; 208(1-2):1-11. PubMed ID: 11064206
[TBL] [Abstract][Full Text] [Related]
35. Factors affecting the deposition of inhaled porous drug particles.
Musante CJ; Schroeter JD; Rosati JA; Crowder TM; Hickey AJ; Martonen TB
J Pharm Sci; 2002 Jul; 91(7):1590-600. PubMed ID: 12115821
[TBL] [Abstract][Full Text] [Related]
36. Size-Limited Penetration of Nanoparticles into Porcine Respiratory Mucus after Aerosol Deposition.
Murgia X; Pawelzyk P; Schaefer UF; Wagner C; Willenbacher N; Lehr CM
Biomacromolecules; 2016 Apr; 17(4):1536-42. PubMed ID: 26957140
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery.
Meenach SA; Kim YJ; Kauffman KJ; Kanthamneni N; Bachelder EM; Ainslie KM
Mol Pharm; 2012 Feb; 9(2):290-8. PubMed ID: 22149217
[TBL] [Abstract][Full Text] [Related]
38. The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function.
Kreft ME; Jerman UD; Lasič E; Hevir-Kene N; Rižner TL; Peternel L; Kristan K
Eur J Pharm Sci; 2015 Mar; 69():1-9. PubMed ID: 25555374
[TBL] [Abstract][Full Text] [Related]
39. Recent advances in pulmonary drug delivery using large, porous inhaled particles.
Edwards DA; Ben-Jebria A; Langer R
J Appl Physiol (1985); 1998 Aug; 85(2):379-85. PubMed ID: 9688708
[TBL] [Abstract][Full Text] [Related]
40. A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations.
Bur M; Rothen-Rutishauser B; Huwer H; Lehr CM
Eur J Pharm Biopharm; 2009 Jun; 72(2):350-7. PubMed ID: 18771729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
